INTERVIEWS

Dr. Ayellet Segrè, PhD, Genetic Biostatistician Assistant Scientist at Massachusetts Eye and Ear, and Harvard Medical School Assistant Professor of Ophthalmology discusses her recent research “Integrating Gene Regulation and Single Cell Expression with Genetic Associations Identifies Genes and Cell Types Contributing to POAG Risk and IOP.”    

The role of practitioner in guiding a mother during pregnancy, both pre, during and after, is essential to supporting the birth of a healthy baby. Gerald Quigley, member of the Perdays pregnancy nutrition brand’s Advisory Board talks best in class pregnancy nutrition and the role of practitioner in this important time.

Amanda Rees is the CEO and Co-founder of Bold, a digital health company that provides clinical exercise programs to prevent falls, manage arthritis, and improve functional fitness for older adults. A recent study published in the Journal of Medical Internet Research (JMIR) shows that users of Bold’s Fall Prevention Program demonstrate a 46% decrease in annualized falls per year and 206% increase in weekly minutes of physical activity. She will discuss the importance of exercise and behavior change in closing the gap between health span and life span, and how the company works with healthcare organizations to help members age boldly.

Newly appointed president of Clarius Mobile Health, Ohad Arazi, discusses the convergence of handheld ultrasound and artificial intelligence to make medical imaging accessible in many new care settings, from orthopaedics and emergency services to medical aesthetics and fertility. 

City of Hope patient Christal Love is here to share her personal breast cancer journey. After receiving suboptimal cancer care, Love sought a second opinion and found City of Hope, a compassionate cancer research and treatment organization in Los Angeles. She has learned to always ask her care team questions and champion what she thinks is right for her. Love has been cancer-free for five years and recalls how she stopped using products containing parabens after she was diagnosed with breast cancer at the age of 39. Love strongly believes in making sure women know the importance of taking the proper precautions when using everyday personal care products and is happy to share her story as an example of how she changed her lifestyle after a cancer diagnosis. Find out more about City of Hope at  www.cityofhope.org.

Dr. Pichamol Jirapinyo, MD, MPH, Associate Director of Bariatric Endoscopy at Brigham and Women’s Hospital discusses her study on Endoscopic Gastric Plication and how it is able to reduce portosystemic pressure gradients in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis, which was presented at the 2022 Digestive Disease Week (DDW) conference. 

Dr. Barbara Shinn-Cunningham, PhD, Carnegie Mellon University professor and Director of Carnegie Mellon Neuroscience Institute discusses the common condition of speech-in-noise difficulty and the breakthrough research conducted over the last decade that suggests that damage to cochlear synapses, the connection between cochlear hair cells and auditory nerve fibers, plays a central role in this condition. She talks about the social and cognitive impact of hearing loss, recent advances that helped to identify cochlear synaptopathy as an underlying cause, and a specific update on Otonomy, the only company with a drug treatment in clinical trials that offers potential for repair.

Dr. Daniel Teper, CEO and co-founder of Cytovia Therapeutics discusses being the first company combining stem cell engineering and multispecific antibodies to empower natural killer (NK) cells to fight cancer through a two-punch approach. The company’s gene-edited induced pluripotent stem cells (iPSC) NK Cell and NK Cell-engager antibody platforms provide significant benefits over existing cell therapies in terms of accessibility, clinical safety, efficacy, and manufacturing. Clinical trials are already planned and will be conducted globally leveraging Cytovia’s strategic collaborations. He also talks about new data presented at the American Association for Cancer Research 2022 meeting providing preclinical in vivo and in vitro validation of two of their multispecific antibody proprietary therapies, one to treat hepatocellular carcinoma (HCC), both alone and with stem cell-derived natural killer cells, and the other to treat multiple myeloma (MM) by targeting different binding sites. 

Dr. Emmy Betz, MD, MPH, Professor, Department of Emergency Medicine, University of Colorado School of Medicine​ talks about her presentation on why we need to work in the middle ground to achieve gun safety, ​which was presented at the PM22 conference in Denver.​

Dr. M. Tonette Krousel-Wood, President, American College of Preventive Medicine talks about her presentation on the perceived COVID-19’s impact over today’s clinical preventive services, which was presented at the PM22 conference in Denver.